133 related articles for article (PubMed ID: 15448811)
1. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma.
Fonseca GN; Srougi M; Leite KR; Nesrallah LJ; Ortiz V
Sao Paulo Med J; 2004 May; 122(3):124-7. PubMed ID: 15448811
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma.
Leite KR; Srougi M; Nesralhah LJ; Camara-Lopes LH
Braz J Med Biol Res; 1999 Mar; 32(3):283-8. PubMed ID: 10347785
[TBL] [Abstract][Full Text] [Related]
3. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
4. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
5. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications.
Mydlo JH; Kral JG; Volpe M; Axotis C; Macchia RJ; Pertschuk LP
Eur Urol; 1998; 34(5):426-32. PubMed ID: 9803006
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
7. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
9. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium.
Ioffe OB; Papadimitriou JC; Drachenberg CB
Hum Pathol; 1998 Oct; 29(10):1150-9. PubMed ID: 9781657
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
11. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma.
Niemhom S; Kitazawa S; Murao S; Kunachak S; Maeda S
Cancer Lett; 2000 Nov; 160(2):199-208. PubMed ID: 11053650
[TBL] [Abstract][Full Text] [Related]
13. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
14. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy.
Nassif AE; Tâmbara Filho R
Rev Col Bras Cir; 2010 Oct; 37(5):338-44. PubMed ID: 21180999
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.
Yaman O; Ozdiler E; Orhan D; Sak SD; Baltaci S; Tulunay O; Göğüş O
Urol Int; 1997; 58(4):199-202. PubMed ID: 9253117
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma.
Felix A; El-Naggar AK; Press MF; Ordonez NG; Fonseca I; Tucker SL; Luna MA; Batsakis JG
Hum Pathol; 1996 Jun; 27(6):561-6. PubMed ID: 8666365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
